You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
